ArticleSarcoma2020

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.

Kristin Baird et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.